Granules India stock crashes on USFDA concerns

The USFDA issued six observations to Granules India’s Gagillapur facility in Hyderabad after an inspection from August 26 to September 6. The company is committed to addressing these issues promptly and will submit its response within the stipulated time frame. This inspection covered both cGMP and PAI processes, significantly impacting the company’s stock price.